In the BioHarmony Drug Report Database
Docetaxel
Docefrez, Docetaxel, Taxotere, Docetaxel Winthrop, Docetaxel Zentiva (docetaxel) is a small molecule pharmaceutical. Docetaxel was first approved as Docefrez on 1995-11-27. It is used to treat breast neoplasms, head and neck neoplasms, melanoma, non-small-cell lung carcinoma, and ovarian neoplasms amongst others in the USA. It has been approved in Europe to treat adenocarcinoma, breast neoplasms, head and neck neoplasms, non-small-cell lung carcinoma, and prostatic neoplasms amongst others. The pharmaceutical is active against tubulin beta chain. Docetaxel’s patents are valid until 2033-09-30 (FDA).
Trade Name
|
Docetaxel Winthrop, Docetaxel Zentiva, Taxotere |
|---|---|
Common Name
|
docetaxel |
ChEMBL ID
|
CHEMBL3545252 |
Indication
|
adenocarcinoma, breast neoplasms, head and neck neoplasms, melanoma, non-small-cell lung carcinoma, ovarian neoplasms, pancreatic neoplasms, prostatic neoplasms, soft tissue neoplasms, stomach neoplasms |
Drug Class
|
Antineoplastics, taxane derivatives |
Image (chem structure or protein)